Cell-cycle dysregulation and the molecular mechanisms of prostate cancer.

D. F. Amanatullah, A. T. Reutens, B. T. Zafonte, M. Fu, Sridhar Mani, R. G. Pestell

Research output: Contribution to journalArticle

43 Citations (Scopus)

Abstract

Prostate cancer is the most common cause of non-cutaneous cancer in men and although frequently latent is the second commonest cause of death. Screening for the disease was historically based on symptoms of urethral obstruction, clinical examination of the prostate gland and serum measurements of prostate specific antigen. As prostate cancer growth in the early stages is enhanced by androgens, the mainstay of therapy has been androgen ablation by pharmaco-therapeutic or surgical means. The subsequent development of androgen therapy resistant prostate cancer in many patients, for whom therapeutic options remain limited, has led researchers to focus attention on understanding the molecular genetics of prostate cancer. The array of genetic abnormalities observed in prostate tumors, which include changes in components of the cell cycle, suggest the disease is quite heterogeneous and may require further sub-classification based on genetic markers. Such analyses may lead to identification of relevant new prognostic and therapeutic indicators. The advent of transgenic mouse models of prostate cancer may provide a critical tool for the implementation of rational genetic based therapeutics and alternate drug design.

Original languageEnglish (US)
JournalFrontiers in Bioscience
Volume5
StatePublished - 2000

Fingerprint

Androgens
Prostatic Neoplasms
Cell Cycle
Cells
Prostate-Specific Antigen
Ablation
Tumors
Prostate
Screening
Therapeutics
Urethral Obstruction
Drug Design
Genetic Markers
Pharmaceutical Preparations
Transgenic Mice
Molecular Biology
Cause of Death
Neoplasms
Research Personnel
Growth

Cite this

Amanatullah, D. F., Reutens, A. T., Zafonte, B. T., Fu, M., Mani, S., & Pestell, R. G. (2000). Cell-cycle dysregulation and the molecular mechanisms of prostate cancer. Frontiers in Bioscience, 5.

Cell-cycle dysregulation and the molecular mechanisms of prostate cancer. / Amanatullah, D. F.; Reutens, A. T.; Zafonte, B. T.; Fu, M.; Mani, Sridhar; Pestell, R. G.

In: Frontiers in Bioscience, Vol. 5, 2000.

Research output: Contribution to journalArticle

Amanatullah, DF, Reutens, AT, Zafonte, BT, Fu, M, Mani, S & Pestell, RG 2000, 'Cell-cycle dysregulation and the molecular mechanisms of prostate cancer.', Frontiers in Bioscience, vol. 5.
Amanatullah, D. F. ; Reutens, A. T. ; Zafonte, B. T. ; Fu, M. ; Mani, Sridhar ; Pestell, R. G. / Cell-cycle dysregulation and the molecular mechanisms of prostate cancer. In: Frontiers in Bioscience. 2000 ; Vol. 5.
@article{e0123888e9004db9a09852f22af8ba13,
title = "Cell-cycle dysregulation and the molecular mechanisms of prostate cancer.",
abstract = "Prostate cancer is the most common cause of non-cutaneous cancer in men and although frequently latent is the second commonest cause of death. Screening for the disease was historically based on symptoms of urethral obstruction, clinical examination of the prostate gland and serum measurements of prostate specific antigen. As prostate cancer growth in the early stages is enhanced by androgens, the mainstay of therapy has been androgen ablation by pharmaco-therapeutic or surgical means. The subsequent development of androgen therapy resistant prostate cancer in many patients, for whom therapeutic options remain limited, has led researchers to focus attention on understanding the molecular genetics of prostate cancer. The array of genetic abnormalities observed in prostate tumors, which include changes in components of the cell cycle, suggest the disease is quite heterogeneous and may require further sub-classification based on genetic markers. Such analyses may lead to identification of relevant new prognostic and therapeutic indicators. The advent of transgenic mouse models of prostate cancer may provide a critical tool for the implementation of rational genetic based therapeutics and alternate drug design.",
author = "Amanatullah, {D. F.} and Reutens, {A. T.} and Zafonte, {B. T.} and M. Fu and Sridhar Mani and Pestell, {R. G.}",
year = "2000",
language = "English (US)",
volume = "5",
journal = "Frontiers in Bioscience - Landmark",
issn = "1093-9946",
publisher = "Frontiers in Bioscience",

}

TY - JOUR

T1 - Cell-cycle dysregulation and the molecular mechanisms of prostate cancer.

AU - Amanatullah, D. F.

AU - Reutens, A. T.

AU - Zafonte, B. T.

AU - Fu, M.

AU - Mani, Sridhar

AU - Pestell, R. G.

PY - 2000

Y1 - 2000

N2 - Prostate cancer is the most common cause of non-cutaneous cancer in men and although frequently latent is the second commonest cause of death. Screening for the disease was historically based on symptoms of urethral obstruction, clinical examination of the prostate gland and serum measurements of prostate specific antigen. As prostate cancer growth in the early stages is enhanced by androgens, the mainstay of therapy has been androgen ablation by pharmaco-therapeutic or surgical means. The subsequent development of androgen therapy resistant prostate cancer in many patients, for whom therapeutic options remain limited, has led researchers to focus attention on understanding the molecular genetics of prostate cancer. The array of genetic abnormalities observed in prostate tumors, which include changes in components of the cell cycle, suggest the disease is quite heterogeneous and may require further sub-classification based on genetic markers. Such analyses may lead to identification of relevant new prognostic and therapeutic indicators. The advent of transgenic mouse models of prostate cancer may provide a critical tool for the implementation of rational genetic based therapeutics and alternate drug design.

AB - Prostate cancer is the most common cause of non-cutaneous cancer in men and although frequently latent is the second commonest cause of death. Screening for the disease was historically based on symptoms of urethral obstruction, clinical examination of the prostate gland and serum measurements of prostate specific antigen. As prostate cancer growth in the early stages is enhanced by androgens, the mainstay of therapy has been androgen ablation by pharmaco-therapeutic or surgical means. The subsequent development of androgen therapy resistant prostate cancer in many patients, for whom therapeutic options remain limited, has led researchers to focus attention on understanding the molecular genetics of prostate cancer. The array of genetic abnormalities observed in prostate tumors, which include changes in components of the cell cycle, suggest the disease is quite heterogeneous and may require further sub-classification based on genetic markers. Such analyses may lead to identification of relevant new prognostic and therapeutic indicators. The advent of transgenic mouse models of prostate cancer may provide a critical tool for the implementation of rational genetic based therapeutics and alternate drug design.

UR - http://www.scopus.com/inward/record.url?scp=0006921489&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0006921489&partnerID=8YFLogxK

M3 - Article

C2 - 10762592

AN - SCOPUS:0006921489

VL - 5

JO - Frontiers in Bioscience - Landmark

JF - Frontiers in Bioscience - Landmark

SN - 1093-9946

ER -